In the same year, Rochester researchers provided similar results on AT-101, which is an R-(−)-gossypol small molecule active in MM resistant-cells in vivo and in vitro, mimicking the BH3 domain of cellular BCL-2 inhibitors. This evidence concerns the gene BCL2 and Miyoshi myopathy.